San Mateo
BioPharm Systems, Inc announced the opening of a new regional office to serve the Europe, Middle East and Africa (EMEA) region. BioPharm Systems, founded in 1995, is a provider of information technology and data management services to the clinical trials industry.
BioPharm is a long-established partner of the Oracle Corporation and provides a wide range of Oracle consulting Services and Products to address needs in clinical data management, electronic data capture, safety and pharmacovigilance reporting, dictionary management, clinical trial management, clinical data analytics and warehousing, systems validation, training and hosting.
Based in North America, BioPharm is now expanding to bring the same services to Clients in the EMEA region, by establishing a new Practice that will be based in the United Kingdom. The practice will be led by Adrian Hampshire, Managing Director EMEA for BioPharm Systems. Adrian Hampshire has served many years in pharmaceutical, biotechnology and CRO organisations in a wide variety of roles.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.